A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

  • STATUS
    Recruiting
  • End date
    Dec 31, 2023
  • participants needed
    301
  • sponsor
    RemeGen Co., Ltd.
Updated on 10 March 2022
cancer
ejection fraction
measurable disease
breast cancer
lapatinib
growth factor
metastasis
neutrophil count
capecitabine
advanced breast cancer
epidermal growth factor receptor
HER2
EGFR
trastuzumab
stage iv breast cancer
erbb2
epidermal growth factor
locally advanced breast cancer
invasive breast cancer
taxane
immunostimulant
mammogram
her1

Summary

This is a randomized, open, parallel-controlled, multicenter, phase II/III, seamless design clinical trial to compare the efficacy and safety of RC48-ADC with capecitabine + lapatinib in locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer and HER2-positive advanced breast cancer with liver metastasis.

Details
Condition Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
Treatment Capecitabine, Lapatinib, RC48-ADC
Clinical Study IdentifierNCT03500380
SponsorRemeGen Co., Ltd.
Last Modified on10 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Voluntarily agree to participate in the study and sign the informed consent form
Subjects aged 18 - 70 years (inclusive), and the subject who have not reached the age of 71 years old will be considered to be ≤ 70 years of age
Expected survival ≥ 12 weeks
ECOG PS score 0 or 1
Female subjects should be surgically sterilized or in post-menopausal status, or agree to use at least one medically accepted contraceptive methods (such as intrauterine device, contraceptive drug or condom) during study treatment period and for up to 6 months after the study treatment is completed, and the blood pregnancy test must be negative within 7 days prior to study enrollment, and they must not be lactating. For male subjects: all the subjects should be surgically sterilized or agree to use one of the medically approved contraceptive methods during the study treatment period and for an additional of 6 months after the end of the study treatment period
Able to understand study requirements, willing and able to comply with study protocol and follow-up procedures
With Adequate Organ Function
Bone marrow function
Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5×109/L; Platelets ≥ 100 ×
Liver function (based on the normal values specified by study site)
L
Serum total bilirubin ≤ 1.5 × the upper limit of normal (ULN); Alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the
absence of liver metastases, while ALT, AST and ALP ≤ 5 × ULN in the presence of liver
Renal function (based on the normal values specified by study site)
metastases
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 60 mL/min as calculated by
Cardiac function
Cockcroft-Gault formula, or 24-hour urine Crcl ≥ 60 mL/min
New York Heart Association (NYHA) classification < Grade III; Left ventricular ejection
fraction ≥ 50%; Tumor Related Criteria
Histologically and/or cytologically confirmed invasive locally advanced or metastatic
breast cancer that is incurable and unresectable
Positive HER2 expression (positive defined as: IHC 3+ or FISH+); previous test results
of HER2 expression provided by the subjects (have to be confirmed by the investigator)
and those obtained from the study site or the central laboratory were both acceptable
With at least one measurable lesion per RECIST v1.1
subject are able to provide samples from primary or metastatic tumor sites for HER2
test (either paraffin blocks, paraffin-embedded sections, or sections prepared using
freshly excised tissues)
With prior taxane therapy (monotherapy or in combination with other drugs, treatment
duration should be ≥ 2 cycles)
With prior adjuvant therapy, have received treatment with trastuzumab or its
biosimilar for patients with locally advanced cancer or metastasis during relapse and
metastasis (monotherapy or in combination with other drugs, such as for ≥ 3 months in
the adjuvant therapy phase, and ≥ 6 weeks in the post-relapse and metastatic phase)
With evidence of tumor progression during or after the most recent treatment as
confirmed by the investigator or with documented history
No more than 2 lines of chemotherapy received after relapse/metastasis. The number of
chemotherapy lines is restricted to chemotherapeutic drugs, and each chemotherapy
regimen is counted as a number of chemotherapy line, excluding targeted drugs and/or
endocrine drugs; the same maintenance treatment as the previous chemotherapy regimen
will not be counted

Exclusion Criteria

Use of investigational drugs within 4 weeks prior to study treatment
Currently suffering from active infections requiring systemic treatment
With history of active tuberculosis
With positive HIV test result
Presence of brain metastases and/or carcinomatous meningitis
Have received major surgeries within 4 weeks prior to study treatment and have not
recovered yet
Have received a live vaccine inoculation within 4 weeks prior to the start of study
drug administration or was scheduled to receive any vaccine during the study
Have experienced arterial/venous thromboembolic events, such as cerebrovascular
accident (including transient ischemic attack), deep vein thrombosis and pulmonary
embolism within 1 year prior to the initiation of study treatment
Suffering uncontrolled systemic diseases, including diabetes, hypertension, pulmonary
fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc
Patients with active hepatitis B or C (HBsAg positive and HBV DNA positive; HCVAb
positive)
Presence of effusion in the third space (including massive hydrothorax or ascites)
that cannot be controlled by drainage or other methods
With known hypersensitivity or delayed-type hypersensitivity to certain components of
RC48-ADC, capecitabine, lapatinib or similar drugs
Currently suffering from active infections requiring systemic treatment
With pre-existing gastrointestinal disorders that may affect absorption, such as
With positive HIV test result
ileus, ulcerative colitis, chronic diarrhea, inability to swallow, and other
conditions that may affect drug administration and absorption
With known psychiatric disorders or drug abuse disorders that might have an impact on
compliance with protocol requirements
Have any other diseases, metabolic disorders, abnormal physical examination findings
or abnormal laboratory test results, which, judged by the investigator, are reasonably
Women who are pregnant or in lactation period or women/men with childbearing plans
to suspect a disease or condition as a contraindication of the study drug, or may
interfere the interpretation of the study results in the future, or that put the
patient at a high risk
Women who are pregnant or during lactation period or women/men with childbearing
plans
Subjects who are estimated to have poor compliance with the clinical study or the
investigator determines that there are other factors not appropriate to participate in
the study
Had any other malignancy within 5 years prior to signing of the informed consent
(except for non-melanoma skin cancer, cervix carcinoma in situ or other tumor that
have been effectively treated and considered to be cured)
Have received prior chemotherapy, radiotherapy, immunotherapy within 4 weeks prior to
the first dose of the study drug
ECOG PS score 0 or 1
Have received hormonal therapy for breast cancer within 2 weeks prior to the start of
study treatment
Patients who received palliative radiotherapy for bone metastases within 2 weeks
With Adequate Organ Function
before the start of study treatment
Bone marrow function
Have received anti-tumor traditional Chinese medicine within 2 weeks prior to the
start of study treatment
Liver function (based on the normal values specified by study site)
Have received capecitabine within 6 months prior to the start of study treatment, or
have failed to respond to prior treatment with capecitabine (including progression
while on capecitabine treatment or maintenance of clinical efficacy for a period of
less than 6 months after treatment), or with intolerance to capecitabine. Patients who
have received capecitabine as adjuvant therapy and have discontinued this therapy for
Renal function (based on the normal values specified by study site)
≥ 6 months are eligible
The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 4.03]
Grade 0-1, with the following exceptions: a). alopecia; b). pigmentation; c)
Cardiac function
long-term toxicity caused by radiotherapy, which are considered as irreversible by the
investigator
With prior systemic therapy with or participation in clinical studies with HER2
tyrosine kinase inhibitors (TKIs)
With prior treatment with T-DM1 or had participated in clinical studies with same
class of drugs
With known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase
deficiency
Inclusion Criteria for Stage 1 Cross-over Period:
Had previously participated in the study of randomized controlled period and received
lapatinib plus capecitabine, and received no anti-tumor treatment after disease
progression (RECIST v1.1 criteria)
The general situation part refers to the selection criteria of the first stage
randomized control period
Exclusion Criteria for Cross-over Period in Stage I:
Have received major surgeries within 4 weeks prior to study treatment and have not
recovered yet
Have received a live vaccine inoculation within 4 weeks prior to the start of study
drug administration or was scheduled to receive any vaccine during the study (except
the COVID-19 vaccine)
Have experienced arterial/venous thromboembolic events, such as cerebrovascular
accident (including transient ischemic attack), deep vein thrombosis and pulmonary
embolism within 1 year prior to the initiation of study treatment
Suffering uncontrolled systemic diseases, including diabetes, hypertension, pulmonary
fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc
Patients with active hepatitis B or C (HBsAg positive and HBV DNA positive; HCVAb
positive)
Presence of effusiona in the third space (including massive hydrothorax or ascites)
that cannot be controlled by drainage or other means
With known hypersensitivity or delayed-type hypersensitivity to certain components of
RC48-ADC or similar drugs
With known psychiatric disorders or drug abuse disorders that might have an impact on
compliance with protocol requirements
Have any other diseases, metabolic disorders, abnormal physical examination findings
or abnormal laboratory test results, which, judged by the investigator, are reasonably
to suspect a disease or condition as a contraindication of the study drug, or may
interfere the interpretation of the study results in the future, or that put the
patient at a high risk
Subjects who are estimated to have poor compliance with the protocol of this
cross-over period or the investigator determines that there are other factors not
appropriate to participate in the study
Presence of brain metastases and/or carcinomatous meningitis. Have received prior
treatment for brain metastases may be considered for participating in this study
provided that the diseases were stable, had no disease progression as confirmed by
imaging examinations within 4 weeks prior to the first dose of the investigational
product (IP), and that all neurological symptoms have recovered to baseline level
without any evidence of newly emerging or spread brain metastases; moreover, treatment
with radiation, surgery or steroids was discontinued at least 14 days prior to the
first dose of study drug. This exception did not include cancerous meningitis, which
should be excluded regardless of the stability of its clinical status
Patients who received palliative radiotherapy for bone metastases within 2 weeks
before the start of study treatment
Received treatment with lapatinib and/or capecitabine within 2 weeks prior to the
first dose of the study drug
The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 4.03]
Grade 0-1, with the following exceptions: a). alopecia; b). pigmentation; c)
long-term toxicity caused by radiotherapy, which are considered as irreversible by the
investigator
Inclusion Criteria for Randomized Controlled Period in Stage II:
The general situation part refers to the selection criteria of the first stage
randomized control period
Exclusion Criteria for Randomized Controlled Period in Stage II:
The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 5.0]
Grade 0-1, with the following exceptions: a). alopecia; b). pigmentation; c)
long-term toxicity caused by radiotherapy, which are considered as irreversible by the
investigator
The remaining parts refer to the exclusion criteria of the first stage randomized
control period
Inclusion Criteria for Cross-over Period in Stage II:
Had previously participated in the study of randomized controlled period and received
lapatinib plus capecitabine, and received no anti-tumor treatment after disease
progression (RECIST v1.1 criteria)
Expected survival ≥ 12 weeks
Female subjects should be surgically sterilized or in post-menopausal status, or agree
to use at least one medically accepted contraceptive methods (such as intrauterine
device, contraceptive drug or condom) during study treatment period and for up to 6
months after the study treatment is completed, and the blood pregnancy test must be
negative within 7 days prior to study enrollment, and they must not be lactating. For
male subjects: all the subjects should be surgically sterilized or agree to use one of
the medically approved contraceptive methods during the study treatment period and for
an additional of 6 months after the end of the study treatment period
Able to understand study requirements, willing and able to comply with study protocol
and follow-up procedures
Hemoglobin ≥ 9 g/dL; Absolute neutrophil count ≥ 1.5×109/L; Platelets ≥ 100 × 109/L
Serum total bilirubin ≤ 1.5 × the upper limit of normal (ULN); Alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 2.5 × ULN in the
absence of liver metastases, while ALT, AST and ALP ≤ 5 × ULN in the presence of liver
metastases
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 60 mL/min as calculated by
Cockcroft-Gault formula, or 24-hour urine Crcl ≥ 60 mL/min
New York Heart Association (NYHA) classification < Grade III; Left ventricular ejection
fraction ≥ 50%
Exclusion Criteria for Cross-over Period in Stage II:
The toxicity of prior anti-tumor therapy had not recovered to CTCAE [Version 5.0]
Grade 0-1, with the following exceptions: a. alopecia; b. pigmentation; c. long-term
toxicity caused by radiotherapy, which are considered as irreversible by the
investigator
The remaining parts refer to the exclusion criteria of the first phase of the
crossover period
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.